Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance

Pharmacological Reports

Volumn 65, Issue 1, 2013, Pages 208-213

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Fibrates; Hemostasis; Metformin; Prediabetes; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NITRIC ACID DERIVATIVE; PLACEBO; THIENOPYRIDINE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DYSLIPIDEMIA; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN SENSITIVITY; MALE; PATIENT COMPLIANCE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84875801170     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)70980-0     Document Type: Article

References (17)

1. Dahlback B: Blood coagulation. Lancet, 2000, 355, 1627-1632.
2. Ha H, Oh EY, Lee HB: The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol, 2009, 5, 203-211.
3. Heinrich J, Assmann G: Fibrinogen and cardiovascular risk. J Cardiovasc Risk, 1995, 2, 197-205.
4. Kannel WB: Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids, 2005, 40, 1215-1220.
5. Kher N,Marsh JD: Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost, 2004, 30, 665-672.
6. KnowlerWC, Barrett-Connor E, Fowler SE, Barrett- Connor E, Fowler SE, Hamman RF, Lachin JM et al.: Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
7. Krysiak R, Gdula-Dymek A, Okopień B: Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients. Pharmacol Rep, 2011, 63, 763-771.
8. Krysiak R, Gdula-Dymek A, Okopień B: Hemostatic effects of simvastatin in subjects with impaired fasting glucose. Pharmacol Rep, 2010, 62, 1090-1098.
9. Krysiak R, Handzlik G, Okopień B: Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose. Pharmacol Rep, 2010, 62, 1099-1107.
10. Krysiak R, Okopien B: Haemostatic effects of simvastatin in subjects with impaired glucose tolerance. Intern Med J, 2011, 41, 473-481.
11. Lamanna C, Monami M, Marchionni N, Mannucci E: Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab, 2011, 13, 221-228.
12. Okopień B, Haberka M, Madej A, Belowski D, Łabuzek K, Krysiak R, Zieliński M et al.: Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep, 2006, 58, 729-735.
13. Okopień B, Krysiak R, Herman ZS: Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab, 2006, 91, 1770-1778.
14. Petersen JL, McGuire DK: Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res, 2005, 2, 9-15.
15. Pruski M, Krysiak R, Okopień B: Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care, 2009, 32, 1421-1424.
16. Spiel AO, Gilbert JC, Jilma B: von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation, 2008, 117, 1449-1459.
17. Warkentin TE: Hemostasis and atherosclerosis. Can J Cardiol, 1995, 11, Suppl C, 29C-34C.